Pancreatic Cancer Research

ResearcherKagoshima UniversityActive in the last 2 years

Yuko Mataki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1206-6384; OpenAlex author ID A5024984243, A5046102908. Sources: OpenAlex.

Their work

Papers
37 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
93
Papers, trials and grants by year

2011: 2 papers · 2012: 4 papers · 2013: 2 papers · 2014: 1 paper · 2015: 4 papers · 2016: 1 paper · 2017: 4 papers · 2018: 6 papers · 2019: 3 papers · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 37

  1. Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial): A Multicenter Randomized Controlled… Co-author DOI 10.1097/sla.0000000000006900↗
  2. Aldehyde Dehydrogenase 2 Activity Assessed Using the Acetaldehyde Breath Test Is Associated with Benign Pancreatic Disease and Pancreatic Cancer: A Case-Contro… Co-author DOI 10.3390/jcm15197543↗
  3. Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter… Co-author DOI 10.1002/ags3.70001↗
  4. Strategies to Target the Tumor-Associated Macrophages in the Immunosuppressive Microenvironment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers17183090↗
  5. Genetic Assessment of Intraductal Papillary Mucinous Neoplasm for Predicting Concomitant Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002373↗
  6. Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis. Co-author DOI 10.1002/jhbp.1127↗
  7. Implications of PD-1, Tim-3, and TIGIT Expression for Cancer Immunity and Pancreatic Cancer Prognosis. Co-author DOI 10.21873/anticanres.15824↗
  8. Effectiveness of Adjuvant Therapy in Patients with Pancreatic Cancer Who Underwent Neoadjuvant Therapy. First author DOI 10.1245/s10434-021-09712-6↗
  9. Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis. Co-author DOI 10.3390/cancers13051057↗
  10. Lung recurrence and its therapeutic strategy in patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.11.015↗
  11. Gene regulation by antitumor miR-130b-5p in pancreatic ductal adenocarcinoma: the clinical significance of oncogenic EPS8. Co-author DOI 10.1038/s10038-019-0584-6↗
  12. Significance of 18F-Fluorodeoxyglucose (FDG) Uptake in Response to Chemoradiotherapy for Pancreatic Cancer. Co-author DOI 10.1245/s10434-018-07098-6↗
  13. Gene Regulation by Antitumor miR-204-5p in Pancreatic Ductal Adenocarcinoma: The Clinical Significance of Direct RACGAP1 Regulation. Co-author DOI 10.3390/cancers11030327↗
  14. Corrigendum to "Clinical impact of circulating tumor cells and therapy response in pancreatic cancer" [43 (6) (2017) 1050-1055]. Co-author DOI 10.1016/j.ejso.2018.03.015↗
  15. A Therapeutic Strategy for Resectable Pancreatic Cancer Based on Risk Factors of Early Recurrence. Co-author DOI 10.1097/mpa.0000000000001066↗
  16. Molecular pathogenesis of pancreatic ductal adenocarcinoma: Impact of passenger strand of pre-miR-148a on gene regulation. Co-author DOI 10.1111/cas.13610↗
  17. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomize… Co-author DOI 10.1186/s13063-018-3002-z↗
  18. Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6357-1↗
  19. Involvement of anti-tumor miR-124-3p and its targets in the pathogenesis of pancreatic ductal adenocarcinoma: direct regulation of ITGA3 and ITGB1 by miR-124-3… Co-author DOI 10.18632/oncotarget.25599↗
  20. Clinical impact of circulating tumor cells and therapy response in pancreatic cancer. Co-author DOI 10.1016/j.ejso.2017.01.241↗
  21. Comparison of proton beam radiotherapy and hyper-fractionated accelerated chemoradiotherapy for locally advanced pancreatic cancer. First author DOI 10.1016/j.pan.2017.07.191↗
  22. Regulation of actin-binding protein ANLN by antitumor miR-217 inhibits cancer cell aggressiveness in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.18261↗
  23. The microRNA expression signature of pancreatic ductal adenocarcinoma by RNA sequencing: anti-tumour functions of the microRNA-216 cluster. Co-author DOI 10.18632/oncotarget.19591↗
  24. Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer. Co-author DOI 10.1007/s00268-016-3477-2↗
  25. Prognostication by inflammation-based score in patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Co-author DOI 10.1016/j.pan.2015.09.015↗
  26. Mucin expression in endoscopic ultrasound-guided fine-needle aspiration specimens is a useful prognostic factor in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000362↗
  27. Assessment of percutaneous laparoscopic ultrasonography-guided core needle biopsy for the advanced diagnosis of unresectable pancreatic cancer. Co-author DOI 10.6092/1590-8577/2891↗
  28. [Radiotherapy for metastatic lesion of pancreatic cancer]. First author PMID 25857007↗
  29. Hypoxia inducible factor-1 alpha plays a pivotal role in hepatic metastasis of pancreatic cancer: an immunohistochemical study. Co-author DOI 10.1002/jhbp.6↗
  30. M2-polarized tumor-associated macrophage infiltration of regional lymph nodes is associated with nodal lymphangiogenesis and occult nodal involvement in pN0 pa… Co-author DOI 10.1097/mpa.0b013e318254f2d1↗
  31. [Examination of resectable and borderline pancreatic cancer treated with neoadjuvant chemoradiation therapy]. Co-author PMID 24393873↗
  32. Epithelial-mesenchymal transition and mesenchymal-epithelial transition via regulation of ZEB-1 and ZEB-2 expression in pancreatic cancer. Co-author DOI 10.1002/jso.23020↗
  33. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer. Co-author DOI 10.1007/s00534-011-0400-y↗
  34. Clinical significance of folate receptor β-expressing tumor-associated macrophages in pancreatic cancer. Co-author DOI 10.1245/s10434-012-2263-0↗
  35. [A case of pancreatic cancer with liver metastasis controlled effectively by chemotherapy based on chemosensitivity test and stereotactic body radiotherapy]. Co-author PMID 22421785↗
  36. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. Co-author DOI 10.1016/j.jss.2009.05.026↗
  37. Advanced staging laparoscopy using single-incision approach for unresectable pancreatic cancer. Co-author DOI 10.1097/sle.0b013e31823bae57↗

Closest collaborators

The 25 strongest of 93 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroshi Kurahara · 29 shared papers, 2011–2024 · strength 2.01
  2. Tetsuya Idichi · 13 shared papers, 2017–2026 · strength 1.62
  3. Kosei Maemura · 26 shared papers, 2011–2021 · strength 1.55
  4. Shoji Natsugoe · 26 shared papers, 2011–2020 · strength 1.47
  5. Takao Ohtsuka · 6 shared papers, 2021–2026 · strength 1.10
  6. Yuto Hozaka · 4 shared papers, 2021–2025 · strength 0.72
  7. Hiroyuki Shinchi · 9 shared papers, 2012–2020 · strength 0.50
  8. Sohei Satoi · 3 shared papers, 2018–2026 · strength 0.46
  9. Naohiko Seki · 6 shared papers, 2017–2019 · strength 0.43
  10. Chieri Nakayama · 2 shared papers, 2022–2025 · strength 0.41
  11. Masayuki Sho · 3 shared papers, 2018–2026 · strength 0.40
  12. Hiroki Yamaue · 3 shared papers, 2018–2026 · strength 0.40
  13. Sonshin Takao · 11 shared papers, 2011–2015 · strength 0.37
  14. Michiyo Higashi · 4 shared papers, 2013–2024 · strength 0.36
  15. Haruhi Fukuhisa · 4 shared papers, 2018–2019 · strength 0.31
  16. Yuichi Nagakawa · 2 shared papers, 2018–2026 · strength 0.29
  17. Seiko Hirono · 2 shared papers, 2018–2026 · strength 0.29
  18. Shinichi Hashimoto · 2 shared papers, 2015–2026 · strength 0.29
  19. Yuki Homma · 2 shared papers, 2022–2025 · strength 0.28
  20. Ryu Matsumoto · 1 shared paper, 2025 · strength 0.27
  21. Shiho Arima · 1 shared paper, 2026 · strength 0.24
  22. Makoto Hinokuchi · 1 shared paper, 2026 · strength 0.24
  23. Yusuke Kamikihara · 1 shared paper, 2026 · strength 0.24
  24. Yasunari Kawabata · 2 shared papers, 2018–2025 · strength 0.23
  25. Ippei Matsumoto · 2 shared papers, 2018–2025 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.